
Orforglipron: Lilly's Oral GLP-1 Pill, Cost, and Launch Timeline
Lilly's once-daily oral GLP-1 is on track for late-2026 FDA approval. The ATTAIN-1 phase 3 trial showed about 14% weight loss without injections, food restrictions, or peptide manufacturing. Here's what's known about cost, launch timing, and how it stacks up.






